Adcytherix SAS. (6/11/24). "Press Release: Adcytherix Launches with € 30m in Seed Funding to Develop Next Generation Antibody Drug Conjugates". Marseille.

	Organisation	Adcytherix SAS
	Organisation 2	Pontifax Venture Capital
	Group	Pontifax (Group)
	Product	antibody-drug conjugate (ADC)
	Product 2	venture capital
	Index term	Adcytherix–SEVERAL: investment, 202406 company launches with seed financing round €30m led by Pontifax Venture Capital
	Index term 2	Emergence Therapeutics–Lilly: investment, 202306 acquisition 100% of Emergence Therapeutics AG by Eli Lilly
	Person	Elands, Jacobus P. M. (Jack) (Adcytherix 202406 CEO + Co-Founder before Emergence Tx + Blink Biomedical + Amakem)
	Person 2	Nussbaum, Ran (Pontifax 200712 Managing Partner also CEO of Biomedix Incubator)

> Vision is to establish a leading ADC developer to treat high unmet need diseases such as cancer.

> Founded by the team that founded and sold Emergence Therapeutics to Eli Lilly and Company.

> Seed round led by Pontifax and includes top-tier life science investors.

Adcytherix SAS today announced its incorporation and seed funding of € 30 million to develop novel antibody-drug-conjugates (ADCs) for the treatment of high unmet need diseases such as cancer.

The company was founded by Jack Elands and Pontifax Venture Capital with Xavier Preville and Carsten Dehning as co-founders. Adcytherix’ senior management team comprises Jack Elands (CEO), Carsten Dehning (CFO) and Xavier Preville (VP, Head of Research and Preclinical Development).

The seed round was led by Pontifax and supported by Pureos Bioventures, RA Capital Management and Dawn Biopharma (a platform controlled by KKR). Management also participated in the seed round.

Jack Elands, CEO of Adcytherix commented: “Our new company has as objective to meet the most urgent need of patients by developing a next generation of ADCs. We are excited that the top tier investors and business partners that supported us before joined us again to help us achieve our goals.”

Ran Nussbaum, Partner at Pontifax Venture Capital added: “We are excited to be part of this new adventure with a superb leadership that worked with us before. ADCs will play a major role in the future of oncology. The team that is leading the company and the syndicate that will support Adcytherix aim to build a well differentiated franchise in the field.”

As part of the seed round financing, Ran Nussbaum and Ohad Hammer of Pontifax, Ximing Ding of Pureos Bioventures, Iyona Rajkomar of Dawn Biopharma and Matthew Hammond of RA Capital Management joined the supervisory committee of Adcytherix.

---- ends ----

For more information please contact:

Adcytherix
Jack Elands, Chief Executive Officer
M: +33 6 38 35 70 08

About Adcytherix

Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer. The company is led by a seasoned management team and is supported by a network of world-leading experts in the field of ADC development. Adcytherix is backed by a syndicate of leading life science investors including Pontifax, Pureos Bioventures, RA Capital Management and Dawn Biopharma (a platform controlled by KKR). Adcytherix is based in Marseille, France. For more information please visit www.adcytherix.com

Record changed: 2024-08-24

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]